BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24913188)

  • 1. Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?
    Deberne M; Ropert S; Billemont B; Daniel C; Chapron J; Goldwasser F
    BMC Cancer; 2014 Jun; 14():416. PubMed ID: 24913188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
    Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
    Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
    Hendriks LE; Derks JL; Postmus PE; Damhuis RA; Houben RM; Troost EG; Hochstenbag MM; Smit EF; Dingemans AM
    Eur J Cancer; 2015 Nov; 51(17):2534-44. PubMed ID: 26323530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and prognostic factors in patients with stable and unstable spinal bone metastases from solid tumors: a retrospective analysis of 915 cases.
    Wolf RJ; Foerster R; Bruckner T; Bostel T; Schlampp I; Debus J; Rief H;
    BMC Cancer; 2016 Jul; 16():528. PubMed ID: 27456003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.
    Bae HM; Lee SH; Kim TM; Kim DW; Yang SC; Wu HG; Kim YW; Heo DS
    Lung Cancer; 2012 Sep; 77(3):572-7. PubMed ID: 22672969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database.
    Wen J; Liu D; Chen D; Chen J; Xu X; Chen C; Zhang F; Duan S; Zhu R; Fan M; Chen Y
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647107
    [No Abstract]   [Full Text] [Related]  

  • 7. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
    Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.
    Wu XT; Zhou JW; Pan LC; Ge T
    J Int Med Res; 2020 May; 48(5):300060520925644. PubMed ID: 32425092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
    Wang Y; Lu BH; Gao Y; Liu YX; Hu MM; Che NY; Lin HF; Li HX; Zhang HM; Zhang TM
    Zhonghua Zhong Liu Za Zhi; 2024 May; 46(5):419-427. PubMed ID: 38742355
    [No Abstract]   [Full Text] [Related]  

  • 10. Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective.
    Paralkar VR; Li T; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):116-21. PubMed ID: 18501099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical analysis of patients with skeletal metastasis of lung cancer.
    Cho YJ; Cho YM; Kim SH; Shin KH; Jung ST; Kim HS
    BMC Cancer; 2019 Apr; 19(1):303. PubMed ID: 30943924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Risk Factors for Bone Metastasis in Non-Small Cell Lung Cancer.
    da Silva GT; Bergmann A; Thuler LCS
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):45-51. PubMed ID: 30678379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
    J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases.
    Rinaldi S; Santoni M; Leoni G; Fiordoliva I; Marcantognini G; Meletani T; Armento G; Santini D; Newsom-Davis T; Tiberi M; Morgese F; Torniai M; Bower M; Berardi R
    Support Care Cancer; 2019 Apr; 27(4):1255-1261. PubMed ID: 30406916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.
    Gibson AJW; Li H; D'Silva A; Tudor RA; Elegbede AA; Otsuka SM; Bebb DG; Cheung WY
    Med Oncol; 2018 Aug; 35(9):117. PubMed ID: 30073425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.